Compare KVHI & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | UNCY |
|---|---|---|
| Founded | 1978 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.2M | 121.9M |
| IPO Year | 1996 | 2021 |
| Metric | KVHI | UNCY |
|---|---|---|
| Price | $6.00 | $6.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 53.9K | ★ 428.0K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,407,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.69 | $3.71 |
| 52 Week High | $6.41 | $11.00 |
| Indicator | KVHI | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 55.47 | 63.99 |
| Support Level | $5.89 | $5.77 |
| Resistance Level | $6.10 | $6.70 |
| Average True Range (ATR) | 0.26 | 0.43 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 82.83 | 71.78 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.